Bioventus (BVS) Capital Expenditures Growth (1y) (2021 - 2026)
Bioventus (BVS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -6.52% |
| 10 | Bioventus | 964.42 Mn | 934.96 Mn | 105.67 Mn | 40.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 40.56% |
| Mar 28, 2026 | -35.35% |
| Dec 31, 2025 | -35.05% |
| Sep 27, 2025 | 2,041.30% |
| Jun 28, 2025 | -632.56% |
| Mar 29, 2025 | 183.85% |
| Dec 31, 2024 | 12,657.14% |
| Sep 28, 2024 | -127.38% |
| Jun 29, 2024 | 96.68% |
| Mar 30, 2024 | -91.83% |
| Dec 31, 2023 | 100.11% |
| Sep 30, 2023 | -79.62% |
| Jul 1, 2023 | -152.75% |
| Apr 1, 2023 | 4,584.21% |
| Dec 31, 2022 | -169.48% |
| Oct 1, 2022 | -57.42% |
| Jul 2, 2022 | 813.38% |
| Apr 2, 2022 | -51.59% |
| Dec 31, 2021 | 548.72% |
| Oct 2, 2021 | 67.16% |